Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) Clinical Trial

— IVF008  

Official title:

First Use of Parental Support Technology(R) for Single Gene Analysis Plus Aneuploidy Screening in Preimplantation Genetic Diagnosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01023048
• Other study ID #: IVF008
• Status: Completed
• Phase: N/A
• First received: November 30, 2009
• Last updated: April 1, 2014
• Start date: November 2009
• Est. completion date: March 2014

Study information

• Verified date: April 2014
• Source: Natera, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Gene Security Network has developed a novel technology called Parental SupportTM (PS) which is used for Preimplantation Genetic Screening/Diagnosis (PGS/D) during in vitro fertilization (IVF). This technology allows IVF physicians to identify embryos, prior to transfer to the uterus, which have the best chance of developing into healthy children. The purpose of this study is to validate clinical use of PS to detect specific genetic mutation(s) known to cause severe inheritable diseases in embryos produced by at-risk couples. This may be done while simultaneously testing these embryos for aneuploidy. This study will allow for first of its kind commercial PGS/D testing to detect disease-associated genetic mutations together with aneuploidy screening.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A to 40 Years

Eligibility

Inclusion Criteria:

• couple (mother and father)at risk to have a child with a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)

• Able to provide laboratory report from commercial CLIA certified laboratory confirming presence of disease associated mutation in mother and/or father

• couple planning to go through IVF and desiring PGD for the specified mutation

• Father (male) willing and able to provide sperm sample

• Maternal (female's) age <40 years (e.g., 39 or younger)

• CVS/Amnio planned once the pregnancy occurs; willing/able to provide amnio/cvs sample for confirmatory testing or provide test results of confirmatory testing performed by an external CLIA certified laboratory.

• FSH <10 (FSH = Follicle Stimulating Hormone. FSH is an indicator of egg quality and rough predictor of egg stimulation success. FSH is routinely measured by the IVF center prior to beginning an IVF cycle.)

Exclusion Criteria:

• Couples without prior documentation of genetic mutation as specified above

• Adult couples where the male partner is not willing, able, or available to provide a semen sample.

• Maternal age >=40 years

• Couple unwilling to have amnio/cvs

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Aneuploidy
• Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)
• Cystic Fibrosis

Intervention

Other:
• preimplantation diagnosis
genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)

Locations

Country	Name	City	State
United States	Gene Security Network	Redwood City	California

Sponsors (1)

Lead Sponsor	Collaborator
Natera, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirm diagnosis through prenatal diagnosis (CVS or amniocentesis)		10-20 weeks post intervention	No